CD34 and myocardial infarction: Although the majority of the clinical trials have been in patients with no-option refractory angina [15,16,17,18,19], CD34+ stem cells have also been investigated in clinical studies for peripheral ischemia [31,32], nonischemic cardiomyopathy [33], myocardial infarction [20], and ischemic stroke [34,35].